Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amvuttra
Pharma
Orphan drug sales to surge past $400B in 2032: report
Despite a few recent policy wins, the orphan drug market remains vulnerable to a more scrutinizing FDA and potential pricing pressures.
Angus Liu
Mar 12, 2026 8:20am
Alnylam hits profitability in Q4 despite Amvuttra revenue miss
Feb 12, 2026 11:05am
Alnylam's ATTR-CM launch blows past estimates again
Oct 30, 2025 8:00am
Pfizer to discontinue low-dose ATTR drug Vyndaqel in US in 2025
Aug 29, 2025 10:40am
Alnylam's market cap jumps past $50B
Aug 1, 2025 7:39am
Alnylam's Amvuttra off to promising start in ATTR-CM
May 1, 2025 11:46am
